{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:08:45Z","timestamp":1787843325715,"version":"build-2784847793"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,2,27]],"date-time":"2017-02-27T00:00:00Z","timestamp":1488153600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s00280-017-3253-5","type":"journal-article","created":{"date-parts":[[2017,2,27]],"date-time":"2017-02-27T12:33:21Z","timestamp":1488198801000},"page":"559-568","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies"],"prefix":"10.1007","volume":"79","author":[{"given":"Peter N.","family":"Morcos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrijn","family":"Bogman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislas","family":"Hubeaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Sturm-Pellanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Ruf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Bordogna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Golding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Zeaiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Abt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdana","family":"Balas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,27]]},"reference":[{"key":"3253_CR1","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ctrv.2013.07.002","volume":"40","author":"C Gridelli","year":"2014","unstructured":"Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F (2014) ALK inhibitors in the treatment of advanced NSCLC. Cancer Treat Rev 40:300\u2013306","journal-title":"Cancer Treat Rev"},{"key":"3253_CR2","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1158\/1078-0432.CCR-10-1591","volume":"17","author":"AT Shaw","year":"2011","unstructured":"Shaw AT, Solomon B (2011) Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res 17:2081\u20132086","journal-title":"Clin Cancer Res"},{"key":"3253_CR3","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","volume":"371","author":"BJ Solomon","year":"1014","unstructured":"Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F, PROFILE (1014) Investigators (2014) First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371:2167\u20132177","journal-title":"N Engl J Med"},{"key":"3253_CR4","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1200\/JCO.2015.65.1406","volume":"34","author":"S Peters","year":"2016","unstructured":"Peters S (2016) Emerging options after progression during crizotinib therapy. J Clin Oncol 34:643\u2013645","journal-title":"J Clin Oncol"},{"key":"3253_CR5","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1470-2045(15)00488-X","volume":"17","author":"AT Shaw","year":"2016","unstructured":"Shaw AT, Gandhi L, Gadgeel S, Riely GJ, Cetnar J, West H, Camidge DR, Socinski MA, Chiappori A, Mekhail T, Chao BH, Borghaei H, Gold KA, Zeaiter A, Bordogna W, Balas B, Puig O, Henschel V, Ou SH, study investigators (2016) Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol 17:234\u2013242","journal-title":"Lancet Oncol"},{"key":"3253_CR6","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1200\/JCO.2015.63.9443","volume":"34","author":"SH Ou","year":"2016","unstructured":"Ou SH, Ahn JS, De Petris L, Govindan R, Yang JC, Hughes B, Lena H, Moro-Sibilot D, Bearz A, Ramirez SV, Mekhail T, Spira A, Bordogna W, Balas B, Morcos PN, Monnet A, Zeaiter A, Kim DW (2016) Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study. J Clin Oncol 34:661\u2013668","journal-title":"J Clin Oncol"},{"key":"3253_CR7","unstructured":"International Conference on Harmonization (2005) Guidance for industry: E14 clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs"},{"key":"3253_CR8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1365-2125.2010.03660.x","volume":"70","author":"C Noord Van","year":"2010","unstructured":"Van Noord C, Eijgelsheim M, Stricker BHC (2010) Drug- and non-drug-associated QT interval prolongation. Br J Clin Pharmacol 70:16\u201323","journal-title":"Br J Clin Pharmacol"},{"key":"3253_CR9","unstructured":"US Food and Drug Administration (2016) Clinical pharmacology and biopharmaceutics review(s) of alectinib. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/208434Orig1s000PharmR.pdf . Accessed 6 July 2016"},{"key":"3253_CR10","doi-asserted-by":"crossref","unstructured":"Hsu JC, Carnac R, Henschel V, Bogman K, Martin-Facklam M, Guerini E, Balas B, Hassan Zeaiter A, Phipps A, Morcos PN, Frey N (2016) Population pharmacokinetics (popPK) and exposure-response (ER) analyses to confirm alectinib 600\u00a0mg BID dose selection in a crizotinib-progressed or intolerant population. J Clin Oncol 34(Suppl; abstr):e20598","DOI":"10.1200\/JCO.2016.34.15_suppl.e20598"},{"key":"3253_CR11","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1542-474X.2003.08413.x","volume":"8","author":"LS Fridericia","year":"2003","unstructured":"Fridericia LS (2003) The duration of systole in an electrocardiogram in normal humans and in patients with heart disease. 1920. Ann Noninvasive Electrocardiol 8:343\u2013351","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"3253_CR12","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.4155\/bio-2016-0068","volume":"8","author":"K Heinig","year":"2016","unstructured":"Heinig K, Miya K, Kamei T, Guerini E, Fraier D, Yu L, Bansal S, Morcos PN (2016) Bioanalysis of alectinib and metabolite M4 in human plasma, cross-validation and impact on PK assessment. Bioanalysis 8:1465\u20131479","journal-title":"Bioanalysis"},{"key":"3253_CR13","unstructured":"Morcos PN, Cleary Y, Guerini E, Dall G, Bogman K, De Petris L, Viteri S, Bordogna W, Yu L, Martin-Facklam M, Phipps A (2016) Clinical drug\u2013drug interactions (DDIs) through cytochrome P450 3 A (CYP3A) for alectinib, a highly selective ALK inhibitor. Clin Pharmacol Ther 99(abstr PI-119):S62"},{"key":"3253_CR14","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S1470-2045(14)70362-6","volume":"15","author":"S Gadgeel","year":"2014","unstructured":"Gadgeel S, Gandhi L, Riely G, Chiappori AA, West HL, Azada MC, Morcos PN, Lee RM, Garcia L, Yu L, Boisserie F, Di Laurenzio L, Golding S, Sato J, Yokoyama S, Tanaka T, Ou SH (2014) Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1\/2 study. Lancet Oncol 15:1119\u20131128","journal-title":"Lancet Oncol"},{"key":"3253_CR15","doi-asserted-by":"crossref","first-page":"12271233","DOI":"10.1080\/14737140.2016.1249857","volume":"16","author":"S Srinivasamaharaj","year":"2016","unstructured":"Srinivasamaharaj S, Salame B, Rios-Perez J, Kloecker G, Perez CA (2016) The role of alectinib in the treatment of advanced ALK-rearranged non-small-cell lung cancer. Expert Rev Anticancer Ther 16:1227\u20131233","journal-title":"Expert Rev Anticancer Ther"},{"key":"3253_CR16","unstructured":"US Food and Drug Administration (2016) Xalkori prescribing information. http:\/\/labeling.pfizer.com\/showlabeling.aspx?id=676 . Accessed 26 July 2016"},{"key":"3253_CR17","unstructured":"US Food and Drug Administration (2015) Zykadia prescribing information. https:\/\/www.pharma.us.novartis.com\/sites\/www.pharma.us.novartis.com\/files\/zykadia.pdf . Accessed 26 July 2016"},{"key":"3253_CR18","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/cncr.28040","volume":"119","author":"SH Ou","year":"2013","unstructured":"Ou SH, Tong WP, Azada M, Siwak-Tapp C, Dy J, Stiber JA (2013) Heart rate decrease during crizotinib treatment and potential correlation to clinical response. Cancer 119:1969\u20131975","journal-title":"Cancer"},{"key":"3253_CR19","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1097\/JTO.0b013e3182307e06","volume":"6","author":"SH Ou","year":"2011","unstructured":"Ou SH, Azada M, Dy J, Stiber JA (2011) Asymptomatic profound sinus bradycardia (heart rate 45) in non-small cell lung cancer patients treated with crizotinib. J Thorac Oncol 6:2135\u20132137","journal-title":"J Thorac Oncol"},{"key":"3253_CR20","unstructured":"US Food and Drug Administration (2014) Clinical\/statistical review of ceritinib. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/205755Orig1s000MedR.pdf . Accessed 26 Aug 2016"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3253-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-017-3253-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3253-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T00:26:19Z","timestamp":1568852779000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-017-3253-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,27]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["3253"],"URL":"https:\/\/doi.org\/10.1007\/s00280-017-3253-5","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,27]]}}}